Trial Information

Inclusion Criteria:

- Histological evidence of high or intermediate grade malignant soft tissue sarcoma, or
cytological evidence in case of presence of multiple metastases. List of eligible and
ineligible tumours are included in the protocol.

- Formalin fixed paraffin embedded tumour blocks and representative H/E
(haematoxylin/eosin) slides must be available for histological central review.
Histological central review is not required before treatment start but is mandatory
within 3 months of registration. Local histopathological diagnosis will be accepted
for entry into the study.

- Presence of measurable disease (according to RECIST criteria).

- Relapsed or refractory disease incurable by surgery or radiotherapy.

- Evidence of objective progression within the last 6 months (RECIST) documented by
measurements of disease,

- Patients must either not be eligible for chemotherapy (for instance because of age,
or because of a biological condition, or because of patient-refusal) or must have
received no more than one combination or two single agents chemotherapy regimen for
advanced disease; (neo) adjuvant therapy is not counted towards this requirement.

- At least 18 years of age

- WHO performance status 0 or 1

- Adequate bone marrow function

- Adequate hepatic function

- Adequate renal function

- PT / PTT less than 1.2 x UNL.

- LVEF above the lower limit of normal for the institution, based on ECHO or MUGA

- Able to swallow and retain oral medication

- Women should not be of childbearing potential and agree to use contraceptive methods
(Oral contraceptives are not allowed).

- Absence of any serious and/or unstable pre-existing medical, psychiatric or other
condition (including lab abnormality) that could interfere with patient safety or
obtaining informed consent.

- Absence of any psychological, familial, sociological or geographical condition
potentially hampering compliance with the study protocol and follow-up schedule;
those conditions should be assessed with the patient before registration in the
trial.

- Written informed consent is given according to ICH/GCP, and national/local
regulations before patient registration/randomization.

Exclusion Criteria:

- history of leptomeningeal or brain metastases

- history of malignancies other than sarcoma (except for basal cell or squamous cell
carcinoma of the skin, carcinoma in situ of the cervix or breast, or the patient has
been free of any other malignancies for greater than 3 years).

- Class II, III or IV heart failure (NYHA classification). A patient who has a history
of class II heart failure and is asymptomatic on treatment may be considered
eligible.

- Uncontrolled or poorly controlled hypertension. Initiation or adjustment of BP
medications is permitted prior to study entry, provided that patient has 3
consecutive BP readings less than 150 / 90 mm Hg each separated by a minimum of 24
hrs. These readings need to be collected prior to registration in the study.

- Women of childbearing potential, who are pregnant (negative serum pregnancy test at
entry) or lactating.

- Concurrent therapy with any specifically prohibited medication or requirement for
using any of these medications during treatment with pazopanib

- Major surgery, hormonal therapy (other than replacement), chemotherapy or
radiotherapy, immunotherapy or other investigational agent within the last 28 days
and/or not recovered from prior therapy within the last 28 days. Use of
erythropoietin is considered supportive care and is permitted. The patient should
have recovered from prior surgery and have no open wounds.

- History of malabsorption syndrome, disease significantly affecting gastrointestinal
function or major resection of the stomach or small bowel that could affect
absorption, distribution, metabolism or excretion of study drugs. No unresolved bowel
obstruction or diarrhea.

Type of Study:

Study Design:

Outcome Measure:

Progression Free Survival at Week 12

Outcome Description:

Progression free survival at week 12 is the number of participants who had a complete response (CR, all detectable tumor had disappeared) or a partial response (PR, a >=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum) or stable disease (SD, no change) 12 weeks from start of therapy, per response evaluation criteria in solid tumors (RECIST v1.0). Clinical progression is progression of disease without documented radiological evidence. Progressive disease (PD), a >=20% increase in target lesions.

Outcome Time Frame:

Week 12

Safety Issue:

No

Principal Investigator

GSK Clinical Trials

Investigator Role:

Study Director

Investigator Affiliation:

GlaxoSmithKline

Authority:

European Union: European Medicines Agency

Study ID:

VEG20002

NCT ID:

NCT00297258

Start Date:

November 2005

Completion Date:

December 2012

Related Keywords:

Sarcoma, Soft Tissue

Sarcoma

Synovial sarcoma

Pazopanib(GW786034)

Adipocytic tumors

Leiomyosarcoma

Phase II

Sarcoma

Name

Location

We are a Cancer Social Network, Resource Directory & Education Hub supporting all those affected by cancer. knowcancer.com is intended to be solely for informational purposes and should not be a substitute for professional medical advice, diagnosis or treatment.